636 related articles for article (PubMed ID: 23063679)
1. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
Köklü S; Tuna Y; Gülşen MT; Demir M; Köksal AŞ; Koçkar MC; Aygün C; Coban S; Ozdil K; Ataseven H; Akin E; Pürnak T; Yüksel I; Ataseven H; Ibiş M; Yildirim B; Nadir I; Küçükazman M; Akbal E; Yüksel O; Başar O; Alkan E; Baykal O
Clin Gastroenterol Hepatol; 2013 Jan; 11(1):88-94. PubMed ID: 23063679
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.
Singal AK; Fontana RJ
Aliment Pharmacol Ther; 2012 Mar; 35(6):674-89. PubMed ID: 22257108
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis.
Peng H; Liu J; Yang M; Tong S; Yin W; Tang H; Hu P; Hu H; Ren H
J Clin Pharmacol; 2014 Feb; 54(2):189-200. PubMed ID: 24105676
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir.
Kwak MS; Choi JW; Lee JS; Kim KA; Suh JH; Cho YS; Won SY; Park BK; Lee CK
J Viral Hepat; 2011 Oct; 18(10):e432-8. PubMed ID: 21914060
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B.
Güzelbulut F; Ovünç AO; Oetinkaya ZA; Senates E; Gökden Y; Saltürk AG; Sezikli M; Ozkara S; Cetinkaya F
Hepatogastroenterology; 2012; 59(114):477-80. PubMed ID: 21940383
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.
Liaw YF; Raptopoulou-Gigi M; Cheinquer H; Sarin SK; Tanwandee T; Leung N; Peng CY; Myers RP; Brown RS; Jeffers L; Tsai N; Bialkowska J; Tang S; Beebe S; Cooney E
Hepatology; 2011 Jul; 54(1):91-100. PubMed ID: 21503940
[TBL] [Abstract][Full Text] [Related]
7. Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis.
Yue-Meng W; Li YH; Wu HM; Yang J; Xu Y; Yang LH; Yang JH
Clin Exp Med; 2017 May; 17(2):233-241. PubMed ID: 27094312
[TBL] [Abstract][Full Text] [Related]
8. First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment.
Ozaras R; Mete B; Ceylan B; Ozgunes N; Gunduz A; Karaosmanoglu H; Cagatay A; Gokturk K; Erdem L; Kocak F; Senates E; Tabak F
Eur J Gastroenterol Hepatol; 2014 Jul; 26(7):774-80. PubMed ID: 24901822
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H
J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
[TBL] [Abstract][Full Text] [Related]
11. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
Viganò M; Colombo M; Aroldi A; Lunghi G; Manenti E; Ponticelli C; Lampertico P
Antivir Ther; 2005; 10(6):709-13. PubMed ID: 16218169
[TBL] [Abstract][Full Text] [Related]
12. Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation.
Cholongitas E; Goulis I; Antoniadis N; Fouzas I; Imvrios G; Giakoustidis D; Giouleme O; Papanikolaou V; Akriviadis E; Vasiliadis T
Transpl Infect Dis; 2016 Oct; 18(5):667-673. PubMed ID: 27421122
[TBL] [Abstract][Full Text] [Related]
13. Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis.
Goyal SK; Dixit VK; Shukla SK; Ghosh J; Behera M; Tripathi M; Gupta N; Ranjan A; Jain AK
Indian J Gastroenterol; 2015 Jul; 34(4):286-91. PubMed ID: 26243587
[TBL] [Abstract][Full Text] [Related]
14. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.
Liaw YF; Sheen IS; Lee CM; Akarca US; Papatheodoridis GV; Suet-Hing Wong F; Chang TT; Horban A; Wang C; Kwan P; Buti M; Prieto M; Berg T; Kitrinos K; Peschell K; Mondou E; Frederick D; Rousseau F; Schiff ER
Hepatology; 2011 Jan; 53(1):62-72. PubMed ID: 21254162
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis.
Hyun JJ; Seo YS; Yoon E; Kim TH; Kim DJ; Kang HS; Jung ES; Kim JH; An H; Kim JH; Yim HJ; Yeon JE; Lee HS; Byun KS; Um SH; Kim CD; Ryu HS
Liver Int; 2012 Apr; 32(4):656-64. PubMed ID: 22099071
[TBL] [Abstract][Full Text] [Related]
16. Similar risk of renal events among patients treated with tenofovir or entecavir for chronic hepatitis B.
Gish RG; Clark MD; Kane SD; Shaw RE; Mangahas MF; Baqai S
Clin Gastroenterol Hepatol; 2012 Aug; 10(8):941-6; quiz e68. PubMed ID: 22507876
[TBL] [Abstract][Full Text] [Related]
17. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis.
Tseng PL; Lu SN; Tung HD; Wang JH; Changchien CS; Lee CM
J Viral Hepat; 2005 Jul; 12(4):386-92. PubMed ID: 15985009
[TBL] [Abstract][Full Text] [Related]
18. Entecavir versus lamivudine in the treatment of chronic hepatitis B patients with hepatic decompensation.
Hsu YC; Mo LR; Chang CY; Perng DS; Tseng CH; Lo GH; Tai CM; Lin CW; Hsu CC; Hsu CY; Huang SC; Lin JT
Antivir Ther; 2012; 17(4):605-12. PubMed ID: 22301517
[TBL] [Abstract][Full Text] [Related]
19. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
Chen FW; Coyle L; Jones BE; Pattullo V
Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice.
Miquel M; Núñez Ó; Trapero-Marugán M; Díaz-Sánchez A; Jiménez M; Arenas J; Canós AP
Ann Hepatol; 2013; 12(2):205-12. PubMed ID: 23396731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]